Press Releases

BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder

Mar 16, 2022

BioCorRx to Present at the Q1 Investor Summit Conference on March 9th

Mar 2, 2022

BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104

Feb 14, 2022

BioCorRx to Present at the H.C. Wainwright BioConnect 2022 Conference

Jan 5, 2022

BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board

Dec 9, 2021

BioCorRx to Participate in the Benzinga All Access Event on December 2nd

Nov 24, 2021

BioCorRx Acquires Intellectual Property for Drug Delivery

Nov 22, 2021

BioCorRx Provides Business Update for the Third Quarter of 2021

Nov 16, 2021

BioCorRx to Present at the Q4 Investor Summit Conference on November 16th

Nov 10, 2021

BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant

Oct 7, 2021